S766 The Effect of Mirikizumab on Fecal Calprotectin and C-Reactive Protein in Phase 3 Studies of Patients With Moderately-to-Severely Active Ulcerative Colitis. (October 2022) - Siegmund, Britta; Samaan, Karen; Li, Xingyuan; Morris, Nathan; Gibble, Theresa Hunter; Redondo, Isabel; Lissoos, Trevor; D'Haens, Geert